NCT04303520View on ClinicalTrials.gov

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 3, 2018

Primary Completion Date

September 30, 2020

Study Completion Date

February 28, 2021

Conditions
CD19-positive ALL
Interventions
BIOLOGICAL

anti-CD19/CD22 CAR-T cells

Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs

DRUG

Fludarabine

30mg/m2/d

DRUG

Cyclophosphamide

500mg/m2/d

Trial Locations (1)

Unknown

RECRUITING

Henan Province of TCM, Zhengzhou

Sponsors
All Listed Sponsors
collaborator

Hrain Biotechnology Co., Ltd.

INDUSTRY

collaborator

First Affiliated Hospital of Wenzhou Medical University

OTHER

collaborator

Second Affiliated Hospital of Nanchang University

OTHER

lead

The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine

OTHER